Peptides for energy and mitochondrial health
Almost every cell in your body runs on fuel made by mitochondria, and how well they work shapes how you feel day to day. This topic covers peptides for energy and the molecules behind it — NAD, which cells use to move energy around, and mitochondrial peptides like MOTS-c and SS-31.
The articles explain the science the way you'd want a friend to: what these compounds are, what studies show, and what's still unproven. All are prescription-only through a licensed provider.
53 articles on this topic
-

MOTS-c Myths: DNA, Gene Therapy and Human Tissue
MOTS-c is a peptide, not DNA or a living cell. Ten claims about gene therapy, stem cells and human tissue, graded against the evidence.
-

What Is a Clinical Hold? FDA Pauses Explained
A clinical hold is an FDA order that delays or stops specified research in people. Lifting it lets that research proceed; it doesn't grant permission to market the drug.
-

NAD+ vs NADH: What Is the Difference?
NAD+ accepts electrons; NADH carries them. Their relationship explains cell chemistry, but it does not establish which product would help a person.
-

Nicotinamide Riboside Heart Failure Trial: Results
A 30-person study found that swallowed NR raised blood NAD and was generally tolerated. It did not establish better heart function or fewer hospital stays.
-

MOTS-c vs CB4211: Related, Not Interchangeable
CB4211 is a modified relative of MOTS-c. Its early human trial cannot establish a MOTS-c dose, side-effect rate, or expected result.
-

What Is an IRB? What Ethics Review Actually Means
An institutional review board checks how a human study treats its participants. Its approval concerns the research plan, not proof that a treatment works.
-

What Is a Surrogate Endpoint? Reading Results
A surrogate endpoint stands in for a health outcome. Here's how to tell a changed lab result from evidence that someone feels or functions better.
-

10 Questions to Ask Before MOTS-c
Ten questions cover the evidence, medicines, medical history, sport rules and follow-up that a MOTS-c visit needs to address.
-

When to Take NAD+: Morning, Night, or Around Workouts?
The October 17, 2026 research searches identified no human trial comparing morning with evening NAD+ injections. Your actual schedule comes from your prescribing clinician and the dispensing pharmacy's instructions.
-

Not on the List: Is NAD+ FDA Approved or Compounded?
Compounded NAD+ is different from an FDA-approved medication and is not FDA-approved. Here is what federal compounding lists, safety alerts, and pharmacy rules mean before you talk with a doctor.
-

MOTS-c and Metformin: Can You Take Them Together?
No published human trial administering MOTS-c with metformin was identified in PubMed and ClinicalTrials.gov searches on October 17, 2026. Combined safety and clinical effects remain unknown, though AMPK research, a human biomarker study, and metformin's label offer context.
-

Is MOTS-c FDA Approved? Still Not
The July committee favored adding both ingredients to a compounding list. FDA staff disagreed, and the vote has not become a rule.
-

NAD IV Infusion Study: What the 2019 Pilot Found
The 2019 pilot tracked NAD+ in blood and urine. It helps explain how an infusion is processed, without establishing better energy or slower aging.
-

Who Discovered SS-31? Szeto and Schiller
Hazel Szeto and Peter Schiller developed SS-31 through work that began with pain-related peptides. Its history runs from an unexpected finding inside cells to elamipretide and Forzinity.
-

10 Questions to Ask Before NAD+
Ten questions explain what an NAD+ visit needs to cover, from your goal and health history to the evidence, pharmacy and follow-up.
-

TAZPOWER Trial: What the Results Actually Show
TAZPOWER missed its main walking and fatigue goals against placebo. Longer follow-up reported gains, with enough uncertainty to require another trial.
-

MOTS-c Anti Aging: Human Benefits Remain Unproven
MOTS-c has not been shown to slow aging in people. Mouse findings and human blood measurements answer narrower questions about aging.
-

MMPOWER-3 Trial: Walking and Fatigue Goals Not Met
After 24 weeks, elamipretide did not beat placebo on walking distance or fatigue. A later genetic subgroup finding led to another trial, not a new verdict.
-

Who Discovered NAD? Where NAD+ Comes From
Harden and Young found NAD's activity in yeast experiments, with a detailed paper in 1906. The vitamin, Nobel and longevity chapters came later.
-

Should I Take NAD+? A Provider's Decision Path
The answer starts with your goal and what is causing the tiredness. Oral supplement findings don't establish what NAD+ injections would do for you.
Page 1 of 3 · 53 articles